4,4-dimethoxy-N,N-dimethylbutan-1-amine

We are 4,4-dimethoxy-N,N-dimethylbutan-1-amine CAS:19718-92-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4,4-dimethoxy-N,N-dimethylbutan-1-amine
CAS.NO:19718-92-4
Synonyms:4,4-dimethoxy-N,N-dimethylbutan-1-amine
4,4-dimethoxy-N,N-dimethylbutanamine
1,1-Dimethoxy-N,N-dimethyl-1-butanamine
4-(Dimethylamino)butyraldehyde Dimethyl Acetal
4,4-Dimethoxy-N,N-dimethylbutylamine
4-dimethylaminobutyraldehyde dimethylacetal
 
Physical and Chemical Properties:
Density 0.9±0.1 g/cm3
Boiling Point 189.2±30.0 °C at 760 mmHg
Molecular Formula C8H19NO2
Molecular Weight 161.242
Flash Point 49.2±11.5 °C
 
Specification:
Appearance:Colorless transparent liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Rizatriptan benzoate(CAS:145202-66-0).

4,4-dimethoxy-N,N-dimethylbutan-1-amine


Related News: Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.16357-59-8 Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms.2,6-Dichloro-4-(trifluoromethyl)nicotinonitrile CAS:13600-42-5 Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms.(2-Fluoro-Benzyl)-Hydrazine CAS:51859-98-4 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.

Related Products
Product Name
Tetramethylpyrazine View Details
quinoxalin-2-ol View Details
Calcium beta-hydroxy-beta-methylbutyrate View Details
CAS:12002-26-5 methyl silicate 51 manufacturer Favipiravir manufacturer (2S,3R,5R)-5-Chloro-2-(((4-methylbenzoyl)oxy)-methyl)tetrahydrofuran-3-yl 4-methylbenzoate manufacturer Sodium Nitrate manufacturer dodecamethylpentasiloxane manufacturer